The Pharmacokinetic and Pharmacodynamic Interactions between the 5-Lipoxygenase Inhibitor Zileuton and the Cyclo-Oxygenase Inhibitor Naproxen in Human Volunteers
- 1 January 1995
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 29 (2) , 112-124
- https://doi.org/10.2165/00003088-199500292-00016
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- In Vitro Plasma Protein Binding of Zileuton and its N-Dehydroxylated MetaboliteClinical Pharmacokinetics, 1995
- Pharmacokinetics and Pharmacodynamics of Zileuton after Oral Administration of Single and Multiple Dose Regimens of Zileuton 600mg in Healthy VolunteersClinical Pharmacokinetics, 1995
- Determination of a New 5-Lipoxygenase Inhibitor, Zileuton, and its Inactive N-Dehydroxylated Metabolite in Plasma by High Performance Liquid ChromatographyClinical Pharmacokinetics, 1995
- The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheepEuropean Journal of Pharmacology, 1992
- Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.Thorax, 1991
- The Effects of a 5-Lipoxygenase Inhibitor on Asthma Induced by Cold, Dry AirNew England Journal of Medicine, 1990
- Selective 5-lipoxygenase inhibition in ulcerative colitisThe Lancet, 1990
- Leukotrienes and inflammationPharmacology & Therapeutics, 1990
- Protein Binding as a Primary Determinant of the Clinical Pharmacokinetic Properties of Non-Steroidal Anti-Inflammatory DrugsClinical Pharmacokinetics, 1987
- Clinical pharmacology of non-steroidal anti-inflammatory drugsPharmacology & Therapeutics, 1987